pharma · Neoplasms，Non-Small Cell Lung Cancer
Tianjin Hemay Pharmaceutical
Tianjin Hemay Pharmaceutical Co., Ltd
Tianjin Hemay Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Neoplasms，Non-Small Cell Lung Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Hemay020
Phase 1 · small molecule · Neoplasms，Non-Small Cell Lung Cancer
Hemay020 for Neoplasms，Non-Small Cell Lung Cancer is a Phase 1 program (small_molecule) at Tianjin Hemay Pharmaceutical Co., Ltd with 1 ClinicalTrials.gov record(s).
Internal code Hemay020P1 2014
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Neoplasms，Non-Small Cell Lung Cancer
- Status
- terminated
- Trials
- 1